0
Article ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 2 ? Original research — experimental, observational, or case-control study. Direct primary evidence. Human Health Effects Nanoplastics Policy & Risk Sign in to save

Nanoparticle-Based Delivery Systems for Vaccines

Vaccines 2022 217 citations ? Citation count from OpenAlex, updated daily. May differ slightly from the publisher's own count. Score: 55 ? 0–100 AI score estimating relevance to the microplastics field. Papers below 30 are filtered from public browse.
Rajashri Bezbaruah, Vivek P. Chavda, Lawandashisha Nongrang, Shahnaz Alom, Kangkan Deka, Tutumoni Kalita, Farak Ali, Bedanta Bhattacharjee, Lalitkumar K. Vora

Summary

This review examines how nanoparticle-based delivery systems are improving vaccine effectiveness by enabling precise control over particle size, shape, and surface properties. Researchers found that these nanovaccines address many shortcomings of traditional vaccines, including low immunogenicity and incomplete protection. The study provides an overview of how advances in chemical and biological engineering are enabling more robust immune responses through improved antigen presentation.

Body Systems

Vaccination is still the most cost-effective way to combat infectious illnesses. Conventional vaccinations may have low immunogenicity and, in most situations, only provide partial protection. A new class of nanoparticle-based vaccinations has shown considerable promise in addressing the majority of the shortcomings of traditional and subunit vaccines. This is due to recent breakthroughs in chemical and biological engineering, which allow for the exact regulation of nanoparticle size, shape, functionality, and surface characteristics, resulting in improved antigen presentation and robust immunogenicity. A blend of physicochemical, immunological, and toxicological experiments can be used to accurately characterize nanovaccines. This narrative review will provide an overview of the current scenario of the nanovaccine.

Sign in to start a discussion.

More Papers Like This

Article Tier 2

Characterization of nanoparticles-based vaccines for COVID-19

Researchers reviewed characterization strategies for nanoparticle-based COVID-19 vaccines, arguing that physicochemical, immunological, and toxicological assays must be combined to adequately assess nanovaccine safety and efficacy, and that rigorous characterization frameworks will be essential for navigating regulatory approval of current and future nanoparticle vaccine platforms.

Article Tier 2

The quest for nanoparticle-powered vaccines in cancer immunotherapy

This review explores how nanoparticles are being developed as cancer vaccine delivery systems to train the immune system to fight tumors more effectively. While focused on cancer immunotherapy rather than microplastics, the research highlights that understanding how nanoparticles interact with the immune system is crucial -- the same principles apply to understanding how nanoplastics may affect immune responses in the body.

Article Tier 2

An Overview of Nanoparticle Properties and Their Bioactivity

This systematic review summarized the properties and bioactivity of nanoparticles (1-100 nm), covering how their size, shape, and surface characteristics influence their behavior in biological systems and their potential applications in microbiology.

Article Tier 2

An updated overview of some factors that influence the biological effects of nanoparticles

This review provides an updated look at how the size, shape, chemical composition, and surface properties of nanoparticles influence their biological effects when they enter the body. Researchers summarize how these physical characteristics determine how nanoparticles interact with proteins, cell receptors, and other biological molecules. The study highlights the importance of understanding these factors for both the safe design of medical nanoparticles and for assessing environmental nanoparticle risks.

Article Tier 2

Current Status and Challenges of Analytical Methods for Evaluation of Size and Surface Modification of Nanoparticle-Based Drug Formulations

Researchers reviewed the analytical methods used to characterize nanoparticle-based drug products — including liposomal therapies and mRNA vaccines — identifying key measurement challenges around polydispersity, non-spherical particles, and surface modifications, and calling for better reference materials and standardization to support next-generation nanomedicine development.

Share this paper